Drug Profile
Cytarabine/etidronic acid
Alternative Names: Etidronate/cytosine arabinoside; Etidronic acid/cytarabine; MBC 11; MBC-11 -29Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MBC Pharma
- Developer MBC Pharma; Osteros Biomedica
- Class Antihypercalcaemics; Antineoplastics; Arabinonucleosides; Bisphosphonates; Calcium regulators; Drug conjugates; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Bone resorption factor inhibitors; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bone metastases
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Bone metastases in Russia (IV)
- 02 Jun 2017 Efficacy and adverse events data from a phase I trial in Bone metastases presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
- 01 Dec 2015 Osteros Biomedica completes a phase I trial in Bone metastases in Russia (IV) (NCT02673060)